A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023

View Dataset
GlaxoSmithKline

Description

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.

Citations (0)

Mentions (0)

Metrics

Dataset Index

0.2

FAIR Score

31%

Citations

0

Mentions

0

Metrics Over Time

Publication Details

DOI

Publisher

Vivli

License

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Assigned Domain

Subfield

Pediatrics, Perinatology and Child Health

Field

Medicine

Domain

Health Sciences

Confidence Score

43%

Source

Scholar Data Model

Keywords

Conditions: Haemophilus influenzae type bInterventions: Haemophilus influenzae Type b Vaccine

Normalization Factors

FT

65.38

CTw

1.00

MTw

1.00